

MELANOMA DISEASE SITE COMMITTEE MEETING

CHELSEA HOTEL, TORONTO, ON ROOM: SCOTT SUNDAY APRIL 30, 2022, 8:00 Am – 12:00 Pm ET

CO-CHAIRS : MARCUS BUTLER AND IAN WATSON SENIOR INVESTIGATOR: JANET DANCEY

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To interpret and address, through clinical and translational research, the disease burden associated with malignant melanoma in Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to malignant melanoma
- To cite and analyze recent results of clinical studies conducted by or in collaboration with CCTG
- To interpret and apply new clinical trial methodologies in the field of clinical research

8: 00 am	Welcome	Marcus Butler
8:05 am	Update on action items from last Meeting	Marcus Butler Ian Watson
8:45 am	Updates on ongoing trials • MEC6 • ME13 • ME13 Sub-study • ME15 (will be presented with S+S WG)	Danielle Vicus Tara Baetz Ian Watson
	Updates from the Working Groups	
9:30 am	 Metastatic + IND Working Group Fecal microbial transplantation to modulate the response to immune checkpoint blockade in patients with advanced melanoma 	Michael Ong Rahima Jamal/Arielle Elkief
10:15 am	Neoadjuvant + Adjuvant Working Group	Xinni Song
11:00 am	 Surgical + Surveillance Working Group ME15 Index Lymph Node (ILN) vs. Therapeutic Lymph Node Dissection (TLND) 	Carolyn Nessim Frances Wright Frances Wright
11:45 am	Other business Next Meeting	Marcus Butler Ian Watson
12:00 pm	Meeting Adjourned	Marcus Butler Ian Watson



CCTG is a CCS national program.